BeOne Medicines Ltd. (06160) Announces Grant of RSUs Involving 16,463 ADSs

Bulletin Express11-14

BeOne Medicines Ltd. (Stock Code: 06160) announced on November 14, 2025, that its compensation committee granted a total of 16,463 restricted share units (RSUs) under the 2016 Share Option and Incentive Plan on November 10, 2025. These units involve 214,019 underlying ordinary shares, representing approximately 0.01% of the company’s total issued shares.

According to the announcement, the RSUs will vest in four equal tranches (25% each year). The aggregate consideration for the grant is nil. The RSUs are not subject to any performance targets or clawback mechanism and are granted to employees of the company. The closing price of the American Depositary Shares (ADSs) on the grant date was US$329.20 per ADS.

After this grant, 60,579,310 underlying shares remain available for future grants under the 2016 Share Option and Incentive Plan. The company stated that making these equity-based awards aligns with its workforce incentive goals and follows its customary compensation practices.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1144131591?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 22:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144131591","market":"us","top_or_hot":-1,"title":"BeOne Medicines Ltd. (06160) Announces Grant of RSUs Involving 16,463 ADSs","media":"Bulletin Express","content":"<p>BeOne Medicines Ltd. (Stock Code: 06160) announced on November 14, 2025, that its compensation committee granted a total of 16,463 restricted share units (RSUs) under the 2016 Share Option and Incentive Plan on November 10, 2025. These units involve 214,019 underlying ordinary shares, representing approximately 0.01% of the company’s total issued shares.</p>\n<p>According to the announcement, the RSUs will vest in four equal tranches (25% each year). The aggregate consideration for the grant is nil. The RSUs are not subject to any performance targets or clawback mechanism and are granted to employees of the company. The closing price of the American Depositary Shares (ADSs) on the grant date was US$329.20 per ADS.</p>\n<p>After this grant, 60,579,310 underlying shares remain available for future grants under the 2016 Share Option and Incentive Plan. The company stated that making these equity-based awards aligns with its workforce incentive goals and follows its customary compensation practices.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BeOne Medicines Ltd. (06160) Announces Grant of RSUs Involving 16,463 ADSs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeOne Medicines Ltd. (06160) Announces Grant of RSUs Involving 16,463 ADSs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-11-14 22:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BeOne Medicines Ltd. (Stock Code: 06160) announced on November 14, 2025, that its compensation committee granted a total of 16,463 restricted share units (RSUs) under the 2016 Share Option and Incentive Plan on November 10, 2025. These units involve 214,019 underlying ordinary shares, representing approximately 0.01% of the company’s total issued shares.</p>\n<p>According to the announcement, the RSUs will vest in four equal tranches (25% each year). The aggregate consideration for the grant is nil. The RSUs are not subject to any performance targets or clawback mechanism and are granted to employees of the company. The closing price of the American Depositary Shares (ADSs) on the grant date was US$329.20 per ADS.</p>\n<p>After this grant, 60,579,310 underlying shares remain available for future grants under the 2016 Share Option and Incentive Plan. The company stated that making these equity-based awards aligns with its workforce incentive goals and follows its customary compensation practices.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06160","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1144131591","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144131591","pubTimestamp":1763130185,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"BeOne Medicines Ltd. (Stock Code: 06160) announced on November 14, 2025, that its compensation committee granted a total of 16,463 restricted share units (RSUs) under the 2016 Share Option and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06160":"百济神州"},"translate_title":"BeOne Medicines Ltd.(06160)宣布授予涉及16,463股ADS的受限制股份单位","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":1},"content_text":"BeOne Medicines Ltd. (Stock Code: 06160) announced on November 14, 2025, that its compensation committee granted a total of 16,463 restricted share units (RSUs) under the 2016 Share Option and Incentive Plan on November 10, 2025. These units involve 214,019 underlying ordinary shares, representing approximately 0.01% of the company’s total issued shares.\nAccording to the announcement, the RSUs will vest in four equal tranches (25% each year). The aggregate consideration for the grant is nil. The RSUs are not subject to any performance targets or clawback mechanism and are granted to employees of the company. The closing price of the American Depositary Shares (ADSs) on the grant date was US$329.20 per ADS.\nAfter this grant, 60,579,310 underlying shares remain available for future grants under the 2016 Share Option and Incentive Plan. The company stated that making these equity-based awards aligns with its workforce incentive goals and follows its customary compensation practices.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1144131591","isCrawlerRequest":true}